SCHEMBL7079205

SCHEMBL7079205

COC(=O)CC(CSc1ccc(O)cc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
MTNR1A P48039 3/20 0.40
MTNR1B P49286 3/20 0.40
KCNA5 P22460 3/20 0.40
ESRRB O95718 2/20 0.40
BACE1 P56817 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
F2 P00734 2/20 0.38
F10 P00742 2/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PRSS1 P07477 1/20 0.37
KMT2A Q03164 1/20 0.37
MMP1 P03956 1/20 0.37
FCER2 P06734 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7073776 0.92 ALDH1A1 (0.51) ALDH1A1MTNR1AMTNR1BKCNA5F2
SCHEMBL7077638 0.88 ALDH1A1 (0.46) ALDH1A1MTNR1AMTNR1BKCNA5LMNA
SCHEMBL7077861 0.87 F2 (0.46) ALDH1A1BACE1L3MBTL1F2F10
SCHEMBL7080815 0.84 GABBR2 (0.51) ALDH1A1MTNR1AMTNR1BBACE1LMNA
SCHEMBL7259084 0.79 ESR1 (0.50) ALDH1A1MTNR1AMTNR1B
SCHEMBL7995142 0.79 ALDH1A1 (0.67) ALDH1A1KCNA5L3MBTL1KMT2A
SCHEMBL7077633 0.77 SMN1; SMN2 (0.40) ALDH1A1L3MBTL1LMNAKMT2A
SCHEMBL7073376 0.75 ALDH1A1 (0.46) ALDH1A1KCNA5ESRRBF2F10
SCHEMBL7239668 0.75 ALDH1A1 (0.57) ALDH1A1KCNA5L3MBTL1LMNAKMT2A
SCHEMBL12268202 0.75 ALDH1A1 (0.61) ALDH1A1KCNA5L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003059872-A1 AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-24 WO disclosed
WO-2003059872-A1 AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-24 WO disclosed